Diterpene Glycosides from Fructus Rubi: Mechanistic Insights into Androgen and TGF-β/Smad Pathway Modulation in Benign Prostatic Hyperplasia

Study Background and Research Question

Benign prostatic hyperplasia (BPH) is a prevalent age-associated disease, underpinned by androgen receptor signaling and complex growth factor-mediated mechanisms. Traditional Chinese medicine (TCM) has long utilized Fructus Rubi (the dried fruit of Rubus chingii Hu) for urinary and kidney-related ailments. However, rigorous mechanistic evidence for its efficacy in BPH was lacking. The reference study (Yu et al., 2025) set out to clarify whether diterpene glycosides from Fructus Rubi (FDS) can directly ameliorate BPH, and to delineate the molecular pathways involved, focusing on androgen receptor (AR) and TGF-β/Smad signaling.

Key Innovation from the Reference Study

The central advance of this research lies in its integrated cellular and animal model approach, which links the anti-BPH effect of a standardized diterpene glycoside extract (FDS) to simultaneous modulation of both androgen-driven and TGF-β/Smad-mediated pathways. Previous studies largely emphasized single-pathway interventions, whereas this work demonstrates that FDS influences both androgen receptor signaling and the S100A2-mediated TGF-β/Smad axis—two nodes crucial for prostate cell proliferation and epithelial-mesenchymal transition (EMT).

Methods and Experimental Design Insights

• Compound Standardization and Target Identification: Diterpene glycosides were extracted from Fructus Rubi and characterized. Drug affinity responsive target stability (DARTS) coupled with mass spectrometry (MS) enabled identification of potential protein targets in cellular lysates.
• Cellular Model: Human RWPE-1 prostate epithelial cells were exposed to dihydrotestosterone (DHT) to induce proliferation and model androgen-driven BPH in vitro. FDS was administered to evaluate its effect on cell proliferation and signaling protein expression.
• Animal Model: Male rats received subcutaneous testosterone propionate (TP) to induce BPH. FDS was administered orally for 28 days to assess its therapeutic effect on prostate size and molecular markers.
• Analytical Techniques: Serum and tissue DHT levels were quantified using enzyme-linked immunosorbent assay (ELISA). Key proteins (AR, PSA, SRD5A2, PCNA, S100A2, TGF-β1, E-cadherin, vimentin, Smad4) were analyzed by western blot, immunohistochemistry, and immunofluorescence.

Protocol Parameters

• DHT induction in RWPE-1 cells: Treat with 10 nM DHT for 24 hours to robustly model androgen-stimulated proliferation.
• BPH induction in rats: Subcutaneous injection of testosterone propionate; FDS oral administration for four weeks.
• Protein expression analysis: Use western blot or immunohistochemistry to quantify AR, PSA, PCNA, S100A2, TGF-β1, and EMT markers after treatment.
• DARTS/MS for target identification: Incubate protein extracts with compound, perform limited proteolysis, then analyze stabilized protein fragments by mass spectrometry.

Core Findings and Why They Matter

According to the reference study, FDS markedly reduced the proliferation of DHT-induced RWPE-1 cells, indicating direct antagonism of androgen-driven growth at the cellular level. In vivo, FDS significantly decreased prostate enlargement in BPH rats, lowered DHT concentrations in both serum and tissue, and suppressed the expression of AR, PSA, PCNA, S100A2, TGF-β1, and Smad4. Notably, FDS upregulated E-cadherin, a marker of epithelial phenotype, suggesting inhibition of EMT—a process linked to prostate tissue remodeling and fibrosis.

Mechanistically, this positions FDS as a multitarget agent: it not only modulates the canonical androgen signaling pathway but also intersects with TGF-β/Smad signaling via S100A2 regulation. This dual-action profile is uncommon among phytotherapeutics and may underlie the observed efficacy in BPH models. The data underscore the therapeutic value of targeting convergent signaling pathways in androgen-driven diseases.

Comparison with Existing Internal Articles and Broader Context

Recent literature and internal resources provide additional context for the modulation of androgen receptor and growth factor signaling in prostate pathobiology. For example, the article "Dihydrotestosterone: Mechanisms and Strategy for Translational Research" outlines how DHT serves as a critical tool to dissect androgen receptor signaling and its crosstalk with EGFR/ERBB2 pathways, with implications for therapy resistance in prostate cancer. The reference study expands on this by showing that DHT not only drives cellular proliferation but also primes TGF-β/Smad-mediated EMT, both of which are suppressed by FDS. This complements the translational perspective offered by internal guides, such as "Dihydrotestosterone (DHT) in Research: Workflows & Optimization", which provides actionable protocols for modeling androgen and EGFR signaling in vitro.

Furthermore, while internal research has emphasized the role of DHT in cancer cell lines and resistance mechanisms (e.g., ECM1-driven anti-androgen resistance), the present study uniquely bridges benign hyperplasia and the intersection of androgen and TGF-β signaling, suggesting possible avenues for cross-disease insight.

Limitations and Transferability

Several limitations should be considered. First, while the rat model recapitulates key aspects of human BPH, species differences in androgen metabolism and prostate structure may affect translational relevance. Second, the precise diterpene glycoside(s) responsible for the observed effects warrant further isolation and characterization. Third, the study does not address potential off-target or systemic effects of FDS, nor does it explore long-term outcomes beyond the 28-day intervention. Finally, while DHT-driven cell and animal models are well-established, they do not fully capture the multifactorial etiology of BPH in aging men.

Why this cross-domain matters, maturity, and limitations

By targeting both androgen and TGF-β/Smad pathways, FDS demonstrates a multitarget mechanism that may inform future research into therapies for androgen-driven diseases outside BPH, such as prostate cancer and fibrosis-associated pathologies. However, the maturity of this cross-domain insight is limited by the absence of direct evidence in malignant or non-prostatic tissues, and further validation is required in human clinical contexts.

Research Support Resources

For researchers seeking to model androgen receptor signaling, EGFR/ERBB2 crosstalk, or to recapitulate the DHT-driven phenotypes described, Dihydrotestosterone (DHT) (SKU B8214, APExBIO) is widely used in both cellular and animal systems. Protocols such as those outlined above can be adapted for studies of BPH, prostate cancer, or androgen-driven EMT. The product information details its suitability for in vitro and in vivo work, and researchers may refer to recent internal comparative guides for optimization tips.